TrialClinical drug investigation2025

Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial.

Dongmei Ji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.